A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

This study is to evaluate the efficacy of CT-P27 measured by quantitative PCR viral load from nasopharyngeal mucosa, compared to placebo.

This study is a Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa study. All enrolled subjects will be given a single dose of 10 mg/kg CT-P27, 20 mg/kg CT-P27, or placebo intravenously and then followed by Day 36.

Inclusion Criteria:

• Healthy Male & Female volunteers

Exclusion Criteria:

• Current clinically significant disease
• Pregnant or nursing mother
• Abnormal pulmonary function, nose or nasopharynx